Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Sparta to develop new camptothecin formulations

April 5, 1996

PEG-rhSOD advancing in preclinical phase

April 5, 1996

Spartaject busulfan to enter phase I

April 5, 1996

Virend entering phase III

April 5, 1996

BILD-1351 for HSV infection

April 5, 1996

New 5alpha-reductase inhibitor from Merck & Co.

March 26, 1996

Multidrug resistance modulator from Pfizer

March 15, 1996

Xenova to evaluate MDR modulator in phase I

March 15, 1996

Eisai describes antitumor sulfonamide

March 15, 1996

OM-174 shows in vivo antitumor activity

March 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...